NCT07459634Phase 2Recruiting

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-01-31Estimated

Enrollment · participants50Estimated

Source updated2026-09-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-20 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Extensive-stage Small-cell Lung Cancer

Treatments or interventions studied

LurbinectedinDrugAlso known as Zepzelca
DurvalumabDrugAlso known as Imfinzi

Primary outcomes · main study measures

measure: Investigator assessed PFS rate; description: Progression Free Survival (PFS) rate is the proportion of participants who have not experienced disease progression (as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) or death from any cause; timeFrame: 6 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history